ClinicalTrials.gg
RecruitingNCT03633708Updated Feb 27, 2026

A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

A Phase 3 interventional study of Etelcalcetide and Standard of Care in Secondary Hyperparathyroidism and Chronic Kidney Disease, sponsored by Amgen. Recruiting at 43 sites in 10 countries. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2019; still recruiting 7 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
0 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary — 2 open to participants now, 2 under way, 2 of them phase 3. etelcalcetide · Hyperparathyroidism, Secondary.

Planned enrollment
9th of 16
56 · median 72
Started
2019
with 1 other
Phase 3
9 of 16
2 open now
Registered
15th of 16
by date
Lead sponsor
11 of 16
Amgen

Among the 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary, this one is the 9th largest by planned enrollment, is one of 2 that started in 2019, is one of 9 in phase 3, and was the 15th registered.

Hyperparathyroidism, Secondary

188 studies on the registry are indexed under Hyperparathyroidism, Secondary; 15 are open to participants now.

Browse Hyperparathyroidism, Secondary studies →

Open to participants now

2 of the 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About etelcalcetide

etelcalcetide: first FDA approval 2017 (PARSABIV), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Hyperparathyroidism, Secondary studies recruiting now, 5 (50%) set no upper age limit and 4 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 0 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary, or all of them as a file.
02

Study summary

This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.

Read the detailed description

SHPT is a common and serious co-morbidity that develops relatively early in the course of CKD, worsens with declining kidney function, and is associated with serious complications in children on dialysis. Children on dialysis experience a wide spectrum of bone abnormalities and growth retardation, in addition to increased risk for cardiovascular morbidity and mortality that manifests early in their adulthood. Traditional therapies for SHPT (eg, vitamin D sterols) are widely used in the pediatric dialysis population, and have the potential to aggravate complications of the disease by increasing serum calcium (Ca), serum phosphorus, and serum Ca times serum phosphorus product.

Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling intact parathyroid hormone (iPTH), Ca, and phosphorus, and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe. Although no previous trials have been conducted in pediatric patients with etelcalcetide (one single dose pharmacokinetic [PK] trial is currently ongoing), Amgen anticipates minimal to moderate risk with a possibility of direct benefit to the pediatric participants (age 28 days to 18 years) in this trial. The burden of complications of SHPT in the pediatric dialysis population and the limitations of current standard therapy, underscore the need for trials of etelcalcetide in these patients to address this unmet medical need and inform the pediatric nephrology community of the potential use of etelcalcetide in children on hemodialysis with critical safety and efficacy data.

03

Conditions studied

  • Secondary Hyperparathyroidism
  • Chronic Kidney Disease

Keywords

  • sHPT
  • CKD
  • pediatric
  • Secondary Hyperparathyroidism
  • Chronic Kidney disease
04

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of 28 days \< 18 years.
  • Dry weight ≥ 7 kg during screening.
  • Diagnosed with CKD and SHPT undergoing hemodialysis at the time of screening.
  • Diagnosis of SHPT with the mean of the 2 consecutive central laboratory iPTH values ≥ 300 pg/mL (32 pmol/L) during screening, on separate days and within 2 weeks of enrolment.
  • Serum corrected calcium (cCa) value ≥ 9.0 mg/dL (2.25 mmol/L) for participants ≥ 2 years of age and older and serum cCa value ≥ 9.6 mg/dL (2.4 mmol/L) for participants 28 days to \< 2 years of age obtained from the central laboratory during screening.
  • Dialysate Ca level ≥ 2.5 mEq/L during screening for at least 4 weeks prior to screening and throughout the duration of the trial.
  • No more than a maximum prescribed dose change of 50% for active vitamin D sterols/phosphate binders/Ca supplements within the 2 weeks prior to screening assessments and remain stable.
  • SHPT not due to vitamin D deficiency, per investigator assessment.

Exclusion criteria

Exclusion Criteria Disease Related

  • History of congenital long syndrome, second or third degree heart block, ventricular tachyarrhythmia's or other conditions associated with prolonged QT interval.
  • Anticipated or scheduled parathyroidectomy during the trial period.
  • Anticipated or scheduled kidney transplant during the trial period.
  • Participant has received a parathyroidectomy within 6 months prior to randomization.

Other Medical Conditions

  • History of other , except non-melanoma skin cancers, cervical or breast ductal carcinoma in situ within the last 5 years.

Prior/Concomitant Therapy

  • Use of concomitant medications that may prolong the corrected QT interval (eg, ondansetron, albuterol, sotalol, amiodarone, erythromycin, or clarithromycin). Refer to CredibleMeds.org for guidance. Certain medications may be allowed based on review by the medical monitor and require additional (ECG) monitoring and potential electrolyte monitoring.
  • Receipt of cinacalcet therapy within 30 days prior to screening assessments and through randomization.
  • Receipt of etelcalcetide within 6 months prior to screening assessments and through randomization.
  • All herbal medicines (eg, St. John's wort), vitamins, and supplements consumed by the participant within the 30 days prior to randomization, and continuing use if applicable, will be reviewed by the Principal Investigator and the Amgen Medical Monitor. Written documentation of the review and Amgen acknowledgment is required for participant participation.
  • Use of any over-the-counter or prescription medications within the 14 days or 5 half-lives (whichever is longer) prior to randomization that are not established therapies for participants with renal disease or other conditions secondary to renal disease will be reviewed by the Principal Investigator and the Amgen Medical Monitor. Written documentation of the review and Amgen acknowledgment is required for participant participation. Paracetamol for analgesia will be allowed.

Prior/Concurrent Clinical Trial Experience • Currently receiving treatment in another device or drug trial, or less than 30 days or 5 half-lives (whichever is longer) since ending treatment on another investigational device or drug trial(s). Other investigational procedures while participating in this trial are excluded.

Diagnostic Assessments During Screening

  • Participant has significant abnormalities on the most recent central laboratory test during the screening period prior to enrollment per the Investigator including but not limited to the following: a. Serum transaminase ( [ALT] or serum glutamic pyruvic transaminase [SGPT], aspartate aminotransferase [AST] or serum glutamic oxaloacetic transaminase [SGOT]) > 2.0 times the (ULN).
  • Corrected QT interval (QTc) > 500 ms, using Bazett's formula.
  • QTc ≥ 450 to ≤ 500 ms, using Bazett's formula, unless written permission to enroll is provided by the investigator after consultation with a pediatric cardiologist.
  • Participant has a ECG abnormality during screening that, in the opinion of the investigator, could pose a risk to participant safety or interfere with the trial evaluation.

Within the 60 days prior to enrollment

  • New onset or worsening of a pre-existing seizure disorder.

Other Exclusions

  • Participants aged 28 days to 6 months of age who were born prematurely at \< 36 weeks gestational age.
  • Female participant is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 3 months after the last dose of etelcalcetide. (Females of should only be included in the trial after a confirmed menstrual period and a negative highly sensitive serum pregnancy test within 7 days prior to the first dose of investigational product).
  • Female participants of childbearing potential unwilling to use 1 highly-effective or acceptable method of during treatment and for an additional 3 months after the last dose of investigational product.
  • Participant has known sensitivity to etelcalcetide or to be administered during dosing.
  • Participant likely to not be available to complete all protocol-required trial visits or procedures, and/or to comply with all required trial procedures (eg, to the best of the participant and investigator's knowledge).
  • History or evidence of any other clinically significant disorder, condition, or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to participant safety or interfere with the trial evaluation, procedures, or completion.
  • Participant has previously entered this trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Etelcalcetide

    Participants are randomized in a 5:1 ratio to receive etelcalcetide in addition to standard of care versus standard of care alone.

    Drug: Etelcalcetide · Other: Standard of Care

  • Active comparator
    Standard of Care

    Participants are randomized in a 5:1 ratio to receive etelcalcetide in addition to standard of care versus standard of care alone.

    Other: Standard of Care

Interventions

  • Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling iPTH, Ca, and phosphorus and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe

    Also known as: Parsabiv

  • OtherStandard of Care

    Standard of care, which can include therapy with vitamin D sterols, Ca supplementation, and/or phosphate binders

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a ≥ 30% Reduction from Baseline in Mean iPTH During the Efficacy Assessment Period (EAP)

    Achievement of at least a 30% reduction from baseline in mean iPTH during the EAP (defined as weeks 20 through 27).

    Time frame: Baseline and Weeks 20-27

  2. Percentage Change from Baseline in Mean iPTH During the EAP

    Percent Change from Baseline in Mean iPTH During EAP (defined as weeks 20 through 27).

    Time frame: Baseline and Weeks 20-27

Secondary outcomes

  1. Maximum Serum Concentration (Cmax) of Etelcalcetide

    Cmax will be collected and reported for the etelcalcetide arm only.

    Time frame: 10-30 minutes post dose on Day 1 and 10-30 minutes post dose on Weeks 5, 9, 13, 17, and 21

  2. Minimum Serum Concentration (Cmin) of Etelcalcetide

    Cmin will be collected and reported for the etelcalcetide arm only.

    Time frame: 10-30 minutes post dose on Day 1 and 10-30 minutes post dose on Weeks 5, 9, 13, 17, and 21

  3. Number of Participants who Experienced Adverse Events (AEs)

    To characterize the safety of etelcalcetide treatment based on adverse events. Nature, frequency, severity, and relationship to treatment of all adverse events, including those of special interest reported during the trial.

    Time frame: Day 1 to 30 days after last dose of etelcalcetide (up to approximately 30 weeks)

  4. Frequency of Hypocalcemia

    Occurrence of hypocalcemia at any point in time, assessed by serum chemistry.

    Time frame: Up to approximately 30 Weeks

  5. Number of Participants with Corrected Serum Ca Levels at any Time During the Trial

    Occurrence of corrected serum Ca levels \<8.0 mg/dL (2.0 mmol/L) for participants 2 to \< 18 years of age and \<8.6 mg/dL (2.15 mmol/L) for participants 28 days to \<2 years of age during the trial.

    Time frame: Up to approximately 30 Weeks

  6. Number of Participants with Serum Phosphorous Levels Below Normal by Age Group

    Occurrence of serum phosphorous levels below the lower limit of normal by age group.

    Time frame: Up to approximately 30 Weeks

  7. Number of Participants with Predialysis iPTH Levels Below Normal by Age Group

    Occurrence of predialysis iPTH levels below the lower limit of normal by age group.

    Time frame: Up to approximately 30 Weeks

  8. Change from Baseline in Systolic Blood Pressure

    To characterize the safety of etelcalcetide treatment based on vital signs.

    Time frame: Week -2, Week -1, Day1, and Weeks 4, 8, 12, 16, 20, 24, and 27

  9. Change from Baseline in Diastolic Blood Pressure

    To characterize the safety of etelcalcetide treatment based on vital signs.

    Time frame: Week -2, Week -1, Day1, and Weeks 4, 8, 12, 16, 20, 24, and 27

  10. Change from Baseline in Heart Rate

    To characterize the safety of etelcalcetide treatment based on vital signs.

    Time frame: Week -2, Week -1, Day1, and Weeks 4, 8, 12, 16, 20, 24, and 27

  11. Change in Tanner Stage

    Changes in tanner stage at scheduled visits.

    Time frame: Week -2 and Week 27

  12. Change in Height

    Changes in height at scheduled visits.

    Time frame: Day 1 and Week 27

  13. Change in Weight

    Changes in weight at scheduled visits.

    Time frame: Week -2, Day 1, and Week 27

  14. Number of Participants Achieving ≥ 30% Reduction in iPTH from Baseline on two Consecutive Visits

    To characterize change in laboratory markers of CKD following etelcalcetide treatment.

    Time frame: Up to approximately 30 Weeks

  15. Mean Change from Baseline in Predialysis iPTH from Baseline during the EAP

    Mean change from baseline in predialysis iPTH during the EAP (defined as weeks 20 through 27).

    Time frame: Baseline and Weeks 20-27

  16. Percentage Change from Baseline in Corrected Total Serum Ca from Baseline During the EAP

    Percentage change from baseline in corrected total serum Ca during the EAP (defined as weeks 20 through 27).

    Time frame: Baseline and Weeks 20-27

  17. Percentage Change from Baseline in Corrected Total Serum Phosphorous from Baseline During the EAP

    Percentage change from baseline in corrected total serum phosphorous during the EAP (defined as weeks 20 through 27).

    Time frame: Baseline and Weeks 20-27

07

Study locations

19 of 43 sites recruiting
  • Childrens Hospital of Los Angeles
    Los Angeles, California 90027, United States
    Recruiting
  • Childrens Hospital Colorado
    Aurora, Colorado 80045, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Childrens Mercy Hospital
    Kansas City, Missouri 64108, United States
    Recruiting
  • Mount Sinai Kidney Center - B1 Renal Treatment
    New York, New York 10029, United States
    Completed

    Not enrolling at this site — choose another above.

  • Cincinnati Childrens Hospital Medical Center
    Cincinnati, Ohio 45229, United States
    Completed

    Not enrolling at this site — choose another above.

  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
    Recruiting
  • The Childrens Hospital at Oklahoma University Medical Center
    Oklahoma City, Oklahoma 73104, United States
    Completed

    Not enrolling at this site — choose another above.

  • Childrens Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Childrens Medical Center Dallas
    Dallas, Texas 75390, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Primary Childrens Hospital Outpatient Services
    Salt Lake City, Utah 84113, United States
    Recruiting
  • Fresenius Escobar
    Belen de Escobar, Buenos Aires B1625DUG, Argentina
    Terminated

    Not enrolling at this site — choose another above.

  • Hospital Italiano
    Cuidad Autonoma de Buenos Aires, Buenos Aires C1199ABB, Argentina
    Recruiting
  • Centro Infantil Del Rinon
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
    Recruiting
  • Manipal Hospital
    Bangalore, Karnataka 560 017, India
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • KLES Dr Prabhakar Kore Hospital and Medical Research Centre
    Belagavi, Karnataka 590010, India
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fortis Flt Lt Rajan Dhall Hospital
    New Delhi, National Capital Territory of Delhi 110 070, India
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • All India Institute of Medical Sciences
    New Delhi, National Capital Territory of Delhi 110029, India
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sir Ganga Ram Hospital
    New Delhi, National Capital Territory of Delhi 110060, India
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • NRS Medical College and Hospital
    Kolkata, West Bengal 700014, India
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Raja Perempuan Zainab II
    Kota Bharu, Kelantan 15586, Malaysia
    Terminated

    Not enrolling at this site — choose another above.

  • Hospital Wanita Dan Kanak-Kanak Kuala Lumpur
    Kuala Lumpur, Kuala Lumpur 50300, Malaysia
    Terminated

    Not enrolling at this site — choose another above.

  • Hospital TuanKu Jaafar
    Seremban, Negeri Sembilan 70300, Malaysia
    Terminated

    Not enrolling at this site — choose another above.

  • SBHI Pediatrics city clinical hospital of Saint Vladimir
    Moscow, 107014, Russia
    Terminated

    Not enrolling at this site — choose another above.

  • SBHI Children's City Multidisciplinary Clinical Specialized Center of High Medical Technologies
    Saint Petersburg, 198205, Russia
    Completed

    Not enrolling at this site — choose another above.

  • State Budgetary Healthcare Institution Samara Regional Clinical Hospital na V D Seredavin
    Samara, 443095, Russia
    Terminated

    Not enrolling at this site — choose another above.

  • National University Hospital
    Singapore, 119074, Singapore
    Recruiting
  • Asan Medical Center
    Seoul, 05505, South Korea
    Terminated

    Not enrolling at this site — choose another above.

  • Seoul National University Hospital
    Seoul, 110-744, South Korea
    Terminated

    Not enrolling at this site — choose another above.

  • Pusan National University Yangsan Hospital
    Yangsan-si, Gyeongsangnam-do, 50612, South Korea
    Terminated

    Not enrolling at this site — choose another above.

  • Kaohsiung Veterans General Hospital
    Kaohsiung City, 81362, Taiwan
    Terminated

    Not enrolling at this site — choose another above.

  • National Cheng Kung University Hospital
    Tainan, 70403, Taiwan
    Terminated

    Not enrolling at this site — choose another above.

  • National Taiwan University Hospital
    Taipei, 10041, Taiwan
    Recruiting
  • Linkou Chang Gung Memorial Hospital
    Taoyuan, 33305, Taiwan
    Recruiting
  • Hacettepe Universitesi Tip Fakultesi Hastanesi
    Ankara, 06230, Turkey (Türkiye)
    Recruiting
  • Baskent Universitesi Ankara Hastanesi
    Ankara, 06490, Turkey (Türkiye)
    Recruiting
  • Gazi Universitesi Saglik Arastirma ve Uygulama Merkezi Gazi Hastanesi
    Ankara, 06500, Turkey (Türkiye)
    Recruiting
  • Ankara Bilkent Sehir Hastanesi
    Ankara, 06800, Turkey (Türkiye)
    Recruiting
  • Firat Universitesi Tip Fakultesi Hastanesi
    Elâzığ, 23200, Turkey (Türkiye)
    Recruiting
  • Istanbul Universitesi Cerrahpasa Tip Fakultesi
    Istanbul, 34098, Turkey (Türkiye)
    Recruiting
  • Marmara Universitesi Tip Fakultesi Hastanesi
    Istanbul, 34890, Turkey (Türkiye)
    Recruiting
  • Ege Universitesi Tip Fakultesi Hastanesi
    Izmir, 35040, Turkey (Türkiye)
    Recruiting
  • Erciyes Universitesi Tip Fakultesi Hastanesi
    Kayseri, 38039, Turkey (Türkiye)
    Recruiting
  • National Childrens Specializated Hospital Okhmadit
    Kyiv, 01135, Ukraine
    Terminated

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this trial will be considered beginning 18 months after the trial has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this trial.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen trial/trials in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2019 (actual). Primary completion is estimated for Jan 2029, 117 months after the start.

Of 21 phase 3 interventional studies under Hyperparathyroidism, Secondary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's planned 117 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2018
First posted
Aug 16, 2018
StartActual
Apr 29, 2019
Primary completionEst.
Jan 31, 2029
CompletionEst.
Jan 31, 2029
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03633708
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 16, 2018
Start date
Apr 29, 2019
Primary completion
Jan 31, 2029 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Feb 27, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etelcalcetide

Start the discussion